Novavax Inc. ($NVAX) Stock Forecast: Down 5.1% Today

What is Novavax Inc.?

Novavax (NVAX) is a biotechnology company recognized for its innovative vaccine developments. The overall market sentiment for NVAX today leans towards the bearish side.

Why is Novavax Inc. going down?

NVAX stock is down 5.1% on Nov 10, 2025 16:40

• NVAX posted strong Q3 earnings and revenue, exceeding expectations.
• It received a milestone payment from Sanofi, which boosted its overall performance.
• Despite these positive developments, the market showed bearish behavior, potentially influenced by profit-taking following a recent upward trend.
• Investor caution about the company's growth sustainability may have also contributed to today's bearish movement.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised

NVAX exceeds third-quarter expectations, boosted by a Sanofi milestone payment. It lifts its 2025 sales outlook.

https://www.zacks.com/stock/news/2787961/novavax-q3-earnings-revenues-beat-estimates-25-sales-view-raised

Trending Today

Uniswap ($UNI) Crypto Forecast: Up 29.8% Today

Litecoin ($LTC) Crypto Forecast: Down 5.0% Today

XRP ($XRP) Crypto Forecast: Up 8.5% Today

Digital Turbine, Inc. ($APPS) Stock Forecast: Down 5.1% Today

Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.0% Today

Rivian Automotive Inc. ($RIVN) Stock Forecast: Up 5.1% Today

American Electric Power Company Inc. ($AEP) Stock Forecast: Down 0.4% Today

Duke Energy Corporation (Holding Company) ($DUK) Stock Forecast: Down 0.2% Today

Novavax Inc. ($NVAX) Stock Forecast: Down 5.1% Today

Plug Power Inc. ($PLUG) Stock Forecast: Down 9.2% Today

Novavax Inc. Price History

16.08.2025 - NVAX Stock was up 5.1%

• Novavax (NVAX) showed a robust bullish trend despite the unfavorable situation surrounding COVID-19 vaccine stocks.
• Investors' optimism towards Novavax may stem from confidence in its vaccine candidate or other undisclosed factors driving the stock's performance.
• The positive movement could suggest an overall belief in Novavax's capabilities to overcome regulatory hurdles and achieve favorable outcomes in the future.

08.09.2025 - NVAX Stock was up 6.1%

• NVAX stock had a strong bullish movement, closing at $9.08 with a 4.02% increase.
• The stock might have benefitted from positive news or developments related to its vaccine candidates.
• Despite the overall market rise, NVAX's slide in the headline could be misleading as the stock actually closed higher, indicating underlying strength.
• Investors should keep an eye on upcoming announcements or clinical trial results that could further impact NVAX's stock performance.

01.07.2025 - NVAX Stock was down 5.0%

• The broader market experienced mixed trading today.
• Novavax closed at $6.85, showing a -2.28% shift from the previous trading day.
• Possibly disappointing news related to the company's vaccine development progress or financial performance.
• General market sentiment impacting biotech stocks negatively.
• Investors reacting to potential delays in regulatory approvals or clinical trial results.

25.06.2025 - NVAX Stock was down 8.5%

• Despite Novavax (NVAX) sharing promising results for their bird flu vaccine in primates, the stock experienced a bearish movement.
• The market might have reacted negatively due to profit-taking by investors after a recent uptrend in the stock price.
• Investors could be cautious about the company's ability to translate positive vaccine results into commercial success in the competitive pharmaceutical industry.
• The bearish movement could also be influenced by broader market factors or sector rotation, leading to a sell-off in biotech stocks despite positive news from Novavax.

10.10.2025 - NVAX Stock was down 5.1%

• NVAX posted strong Q3 earnings and revenue, exceeding expectations.
• It received a milestone payment from Sanofi, which boosted its overall performance.
• Despite these positive developments, the market showed bearish behavior, potentially influenced by profit-taking following a recent upward trend.
• Investor caution about the company's growth sustainability may have also contributed to today's bearish movement.

15.09.2025 - NVAX Stock was up 5.2%

• Second-largest shareholder, Shah Capital, a hedge fund, is encouraging Novavax to explore a sale due to ongoing vaccination rollout issues.
• A potential sale could boost investor confidence, driving the stock's upward movement.
• Investors seem hopeful that a sale could unlock value for Novavax, contributing to today's positive market sentiment.

06.07.2025 - NVAX Stock was up 18.4%

• Novavax saw a robust uptrend in its stock price despite prevailing market conditions.
• The decline in Novavax's stock value might be linked to the repercussions of another company's disappointing Q2 performance within the vaccine industry.
• Investors seemed optimistic about Novavax's potential to recover from the drop, which likely fueled the bullish momentum.
• The market's positive outlook on Novavax's advancements in vaccine development may have also played a role in the stock's upward movement.

06.07.2025 - NVAX Stock was up 11.3%

• Novavax (NVAX) reported impressive Q2 earnings and revenue results, surpassing estimates by a significant margin, which likely boosted investor confidence in the company's growth prospects.
• Despite Novavax's positive performance, the stock experienced a slight dip, possibly due to concerns stemming from another company's disappointing Q2 results, which had a negative impact on the entire vaccine sector.
• The broader market saw a more significant dip compared to Novavax, indicating that while there may have been some sector-specific challenges affecting the stock, Novavax managed to outperform the market on that particular day.
• Investors should keep an eye on how Novavax navigates through the challenges in the vaccine sector and capitalizes on its strong earnings to drive future growth and stock performance.

08.06.2025 - NVAX Stock was up 5.6%

• Factors contributing to the bullish movement in NVAX stock include:
• Despite a slight decline in the broader market, NVAX demonstrated resilience by closing higher, showcasing strong investor confidence.
• The potential influence of RFK Jr. in the vaccine approval process may have had a positive impact on NVAX, with the company being mentioned alongside other vaccine manufacturers such as Moderna and Pfizer.
• FDA chief Prasad's decision to restrict COVID-19 vaccine approval to specific groups could have positioned NVAX favorably, potentially increasing demand for its vaccine candidates.
• Growing macro risks like tariffs and inflation may have driven investors to seek safety in healthcare stocks like NVAX, leading to an increase in its price.

04.10.2025 - NVAX Stock was down 5.1%

• Factors contributing to the bearish movement in NVAX stock include market volatility prompting profit-taking, worries regarding the company's vaccine pipeline, pessimism towards the biotech industry, and technical signals indicating a possible trend reversal.

21.07.2025 - NVAX Stock was down 12.2%

• There is bearish sentiment towards Novavax in the options market, indicating pessimism among some investors.
• Novavax recently issued $225 million of convertible notes with a conversion price above the last closing price, sparking concerns about potential dilution for current shareholders.
• The market perceives the convertible notes issuance as a sign of financial strain or the need for additional funding, raising doubts about Novavax's financial stability and growth outlook.
• The convergence of bearish options market activity and the convertible notes offered at a premium conversion price likely contributed to the significant decline in Novavax's stock.

21.07.2025 - NVAX Stock was down 13.0%

• The issuance of $225 million in convertible notes by Novavax has raised concerns among investors about potential dilution, likely contributing to the recent bearish movement in the stock.
• The conversion price of the newly issued notes, set at a 27.5% premium to the last closing price, suggests the possibility of future dilution of existing shares, which has had a negative impact on the stock.
• Investor apprehension regarding Novavax's financial decisions and their potential effects on future earnings has led to a sell-off of the stock.